title: Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study.
abstract: BACKGROUND
  Transcranial magnetic stimulation (TMS) is a noninvasive method to stimulate the cortex, and the treatment of depression is one of its potential therapeutic applications. Three recent meta analyses strongly suggest its benefits in the treatment of depression. The present study investigates whether repetitive TMS (rTMS) accelerates the onset of action and increases the therapeutic effects of amitriptyline.
  
  
  METHODS
  Forty-six outpatients meeting DSM-IV criteria for nonpsychotic depressive episode were randomly assigned to receive rTMS (n = 22) or sham repetitive TMS (sham) (n = 24) during 4 weeks over dorsolateral prefrontal cortex (DLPFC) in this double-blind controlled trial. All patients were concomitantly taking amitriptyline (mean dose 110 mg/d). The rTMS group received 20 sessions (5 sections per week) of 5 Hz rTMS (120% of motor threshold and 1250 pulses per session). Sham stimulation followed the same schedule, however, using a sham coil. The efficacy variables were the Hamilton Depression Rating Scale-17 items (HAM-D/17), the Montgomery-Asberg Depression Rating Scale (MADRS), a Visual Analogue Scale (VAS), and the Clinical Global Impression (CGI). Tolerability was assessed by clinical examination and a safety screening of TMS side effects.
  
  
  RESULTS
  Repetitive TMS had a significantly faster response to amitriptyline. There was a significant decrease in HAM-D/17 scores, already after the first week of treatment (p < .001 compared with baseline and p < .001 compared with sham). The decrease in HAM-D/17 scores in the rTMS group was significantly superior compared with the sham group throughout the study (p < .001 at fourth week).
  
  
  CONCLUSIONS
  Repetitive TMS at 5 Hz accelerated the onset of action and augmented the response to amitriptyline.
authors.affiliation: Institute of Psychiatry, University of São Paulo, Faculty of Medicine, São Paulo-SP, Brazil. drumi@usp.br
authors.forename: Demetrio Ortega
authors.initials: DO
authors.lastname: Rumi
authors.forename: Wagner F
authors.initials: WF
authors.lastname: Gattaz
authors.forename: Sergio Paulo
authors.initials: SP
authors.lastname: Rigonatti
authors.forename: Moacyr Alexandro
authors.initials: MA
authors.lastname: Rosa
authors.forename: Felipe
authors.initials: F
authors.lastname: Fregni
authors.forename: Marina Odebrecht
authors.initials: MO
authors.lastname: Rosa
authors.forename: Carlos
authors.initials: C
authors.lastname: Mansur
authors.forename: Martin Luiz
authors.initials: ML
authors.lastname: Myczkowski
authors.forename: Ricardo Alberto
authors.initials: RA
authors.lastname: Moreno
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Marcolin
mesh_terms: D000328:Adult; D000639:Amitriptyline / Q000627:therapeutic use*; D000704:Analysis of Variance; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003131:Combined Modality Therapy; D003865:Major Depressive Disorder / Q000628:therapy*; D004311:Double-Blind Method; D004599:Electric Stimulation Therapy / Q000379:methods; D004574:Electromagnetic Fields; D005260:Female; D006801:Humans; D008297:Male; D017397:Prefrontal Cortex / Q000503:physiopathology; D011569:Psychiatric Status Rating Scales; D050781:Transcranial Magnetic Stimulation / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000929:Antidepressive Agents, Tricyclic; D000639:Amitriptyline